LONDON --(BUSINESS WIRE)--May 4, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2022 . Financial Summary and Highlights 1 Worldwide sales were $240.2 million , a decrease of 3.0 percent on a

Intuitive monitor featuring patient-tailored approach is now in clinical use in select centers in U.S. and Europe LONDON --(BUSINESS WIRE)--Apr. 8, 2022-- LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today announced receipt of regulatory approvals and the

LONDON --(BUSINESS WIRE)--Mar. 24, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2022 results on Wednesday, May 4, 2022 at 1 p.m.   London time ( 8 a.m. EDT ).

LONDON --(BUSINESS WIRE)--Mar. 14, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 250th unipolar depression patient has been implanted in the RECOVER clinical study , “A P r ospective, Multi-c e nter, Randomized C ontrolled

Study to evaluate effectiveness of hypoglossal nerve stimulation LONDON --(BUSINESS WIRE)--Feb. 24, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the first patient implanted in the investigational device exemption (IDE) clinical

LONDON --(BUSINESS WIRE)--Feb. 23, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2021 . For the fourth quarter of 2021, worldwide sales from continuing operations were $270.1

LONDON --(BUSINESS WIRE)--Jan. 12, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2021 results on Wednesday, February 23, 2022 at 1 p.m.   London time ( 8 a.m. Eastern Time ).